Intellia Therapeutics, Inc. (NTLA)
12.36
+0.16
(+1.27%)
USD |
NASDAQ |
Jun 11, 16:00
12.36
0.00 (0.00%)
After-Hours: 20:00
Intellia Therapeutics Accounts Payable (Quarterly) : 18.80M for March 31, 2026
Accounts Payable (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Accounts Payable (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2026 | 18.80M |
| December 31, 2025 | 20.25M |
| September 30, 2025 | 13.26M |
| June 30, 2025 | 9.802M |
| March 31, 2025 | 12.36M |
| December 31, 2024 | 14.59M |
| September 30, 2024 | 13.14M |
| June 30, 2024 | 18.82M |
| March 31, 2024 | 13.69M |
| December 31, 2023 | 7.452M |
| September 30, 2023 | 3.553M |
| June 30, 2023 | 11.63M |
| March 31, 2023 | 6.89M |
| December 31, 2022 | 5.154M |
| September 30, 2022 | 4.384M |
| June 30, 2022 | 7.515M |
| March 31, 2022 | 10.14M |
| December 31, 2021 | 9.653M |
| September 30, 2021 | 7.47M |
| June 30, 2021 | 6.854M |
| March 31, 2021 | 8.688M |
| Date | Value |
|---|---|
| December 31, 2020 | 10.46M |
| September 30, 2020 | 7.775M |
| June 30, 2020 | 0.007M |
| March 31, 2020 | 3.87M |
| December 31, 2019 | 3.941M |
| September 30, 2019 | 4.548M |
| June 30, 2019 | 1.848M |
| March 31, 2019 | 3.687M |
| December 31, 2018 | 2.708M |
| September 30, 2018 | 1.754M |
| June 30, 2018 | 0.335M |
| March 31, 2018 | 1.916M |
| December 31, 2017 | 2.172M |
| September 30, 2017 | 2.194M |
| June 30, 2017 | 2.267M |
| March 31, 2017 | 1.434M |
| December 31, 2016 | 4.652M |
| September 30, 2016 | 0.657M |
| June 30, 2016 | 1.042M |
| March 31, 2016 | 1.206M |
Accounts Payable Definition
Accounting terminology for money that a company owes to vendors for services or products that it purchased on credit. Accounts payable appear on the balance sheet as a current liability.
Accounts Payable (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Accounts Payable (Quarterly) Benchmarks
| Beam Therapeutics, Inc. | 12.29M |
| Twist Bioscience Corp. | 14.68M |
| Tenaya Therapeutics, Inc. | 1.914M |
| HCW Biologics Inc. | 11.79M |
| Arrowhead Pharmaceuticals, Inc. | 30.75M |